Course: Strategies to Combat Community Challenges with ADCs for HR+/HER2- mBC
CME Credits: 1.00
Released: 2025-05-20
Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic approach for patients with HR+/HER2- breast cancer. ADCs present a unique potential to address the treatment gaps in HR+/HER2- metastatic breast cancer, providing options tailored to patient-specific tumor biology and treatment history. With these advancements in ADC therapies, clinicians must stay updated on the latest clinical data, treatment guidelines, and best practices for managing adverse events. Join an expert panel featuring oncologists Aditya Bardia, MD and Komal Jhaveri, MD to discuss the nuances of treatment sequencing, patient selection, and toxicity management to optimize patient outcomes and patient-centered care.
View Full Course